Species |
Human |
Protein Construction |
VEGF R2/KDR (Ala20-Glu764) Accession # P35968-1 |
mFc (IgG1) |
N-term |
C-term |
|
Purity |
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC |
Endotoxin Level |
Less than 1EU per μg by the LAL method. |
Biological Activity |
Immobilized Human VEGF165 at 1 μg/ml (100μl/well) on the plate can bind VEGF R2/KDR mFc Chimera, Human (Cat.No.: Z03966) |
Expression System |
HEK293 |
Theoretical Molecular Weight |
110 kDa |
Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 150-200 kDa based on Bis-Tris PAGE result. |
Formulation |
Lyophilized from a 0.22 μm filtered solution in PBS, (pH 7.4). |
Reconstitution |
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH2O more than 100 μg/ml. |
Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |

The purity of VEGF R2/KDR mFc Chimera, Human is greater than 95% as determined by SEC-HPLC.

VEGF R2/KDR mFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

Immobilized Human VEGF165,No Tag at 1 μg/ml (100 μl/well) on the plate. Dose response curve for VEGF R2/KDR mFc Chimera, Human with the EC50 of 42.7 ng/ml determined by ELISA.
Target Background |
Vascular endothelial growth factor receptor 2 (VEGFR2) is one kind of tyrosine kinase receptors. VEGFR2 acts as a cell-surface receptor for VEGFA, VEGFB and PGF. It plays an important role in the development of embryonic vasculature, cell survival and cancer cell invasion. VEGFR2 is a key regulator of angiogenesis. |
Synonyms |
CD309; KDR; VEGFR; VEGFR2; VEGFR-21; FLK1; KRD1; Ly73 |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.